Denosumab‐induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings

King, Brian J.; Lehman, Julia S.; Valinotti, Julio C. Sartori

doi:10.1111/cup.13070

Cited by 9 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rarer dermatologic toxicities include lichenoid dermatitis (Figure 3), lichen planus, 26,51 vasculitis, 82 and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome 43 . One patient had an extremely pruritic lichenoid drug eruption, with histopathology showing focal vacuolar interface changes and perivascular lymphohistiocytic infiltrates with eosinophils 52 . Table 2 lists the types of dermatologic toxicities seen with mAbs targeting RANKL.…”

Section: Resultsmentioning

confidence: 99%

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

Background Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non−immune checkpoint inhibitor (non‐ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited. Methods A comprehensive review was conducted on dermatologic toxicities associated with different classes of non‐ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta‐analyses; and case series/reports. Results Dermatologic toxicities were associated with several types of non‐ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non‐ICI mAbs. Immunobullous reactions were rare and a subset of non‐ICI mAbs were associated with the development of vitiligo cAEs. Conclusion Dermatologic toxicities of non‐ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non‐ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.

show abstract

Section: Resultsmentioning

confidence: 99%

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The cutaneous adverse reactions range from benign reactions, including exanthematous or maculopapular eruption (drug rash), photosensitivity, and urticaria, to the severe and potentially life-threatening reactions, such as angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) [107]. In fact, the literature reports a variety of skin manifestations associated with the use of bisphosphonates [108,109], analogues of PTH [110], and denosumab [111][112][113] that the dermatologist must keep in mind and recognize.…”

Section: Other Skin Diseases and Osteoporosis-related Skin Manifestatmentioning

confidence: 99%

Osteoporosis in Skin Diseases

Sirufo

Pietro

Bassino

et al. 2020

IJMS

View full text Add to dashboard Cite

Osteoporosis (OP) is defined as a generalized skeletal disease characterized by low bone mass and an alteration of the microarchitecture that lead to an increase in bone fragility and, therefore, an increased risk of fractures. It must be considered today as a true public health problem and the most widespread metabolic bone disease that affects more than 200 million people worldwide. Under physiological conditions, there is a balance between bone formation and bone resorption necessary for skeletal homeostasis. In pathological situations, this balance is altered in favor of osteoclast (OC)-mediated bone resorption. During chronic inflammation, the balance between bone formation and bone resorption may be considerably affected, contributing to a net prevalence of osteoclastogenesis. Skin diseases are the fourth cause of human disease in the world, affecting approximately one third of the world’s population with a prevalence in elderly men. Inflammation and the various associated cytokine patterns are the basis of both osteoporosis and most skin pathologies. Moreover, dermatological patients also undergo local or systemic treatments with glucocorticoids and immunosuppressants that could increase the risk of osteoporosis. Therefore, particular attention should be paid to bone health in these patients. The purpose of the present review is to take stock of the knowledge in this still quite unexplored field, despite the frequency of such conditions in clinical practice.

show abstract

“…It is administered subcutaneously every 6 months 1 . Although lichenoid eruptions to various drugs have been reported, a PubMed search revealed only one reported case of lichenoid reaction secondary to denosumab 2 . The World Health Organization pharmaceuticals newsletter of 2016 discussed 14 cases of possible denosumab‐induced LP 3 .…”

Section: Figurementioning

confidence: 99%

“…1 Although lichenoid eruptions to various drugs have been reported, a PubMed search revealed only one reported case of lichenoid reaction secondary to denosumab. 2 The World Health Organization pharmaceuticals newsletter of 2016 discussed 14 cases of possible denosumab-induced LP. 3 All cases documented to date have been women who were being treated for osteoporosis.…”

mentioning

confidence: 99%